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Mycophenolate mofetil (MMF) is an antimetabolite with a 
potent inhibitory effect on proliferation of T and B lymphocytes 
used since the early 1990s for the prevention of acute allograft 
rejection after organ transplant. MMF is also widely used for 
the treatment of a variety of rheumatic diseases (RDs) and 
their pulmonary involvement. Interstitial lung disease (ILD) is 
a heterogeneous group of progressive fibrotic diseases of the 
lung, which is often secondary to RD and represents a major 
cause of morbidity and mortality. MMF is considered the 
main alternative to cyclophosphamide as a first-line agent to 
treat RD-related ILD or as possible maintenance therapy after 
cyclophosphamide, with a lower rate of side-effects. However, as 
for other immunosuppressive agents, the use of MMF in RD-ILD 
is supported by poor scientific evidence. In this narrative review, 
we describe the available data and recent advances on the 
effectiveness and safety of MMF for the treatment of ILD related 
to RD, including rheumatoid arthritis, systemic sclerosis, primary 
Sjögren syndrome, systemic lupus erythematosus, idiopathic 
inflammatory myopathies, undifferentiated connective tissue 
disease, interstitial pneumonia with autoimmune features and 
antineutrophil cytoplasmic antibody-associated vasculitis. 
Keywords: connective tissue diseases, efficacy, interstitial 
lung disease, lung fibrosis, mycophenolate mofetil, rheumatic 
diseases, safety.
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Introduction
Mycophenolate mofetil (MMF) is a prodrug of mycophenolic 
acid (MPA), an inhibitor of inosine monophosphate 
dehydrogenase, which inhibits de novo guanosine nucleotide 
synthesis and exerts a series of immunosuppressive effects.1 
MMF has been used since the early 1990s for the prevention 
of acute allograft rejection and is also widely used for the 
treatment of a variety of rheumatic diseases (RDs) (dose usually 
ranging from 1 to 3 g).2,3
Interstitial lung disease (ILD) is a heterogeneous group of 
progressive fibrotic diseases of the lung, often secondary to 
RD, and represents a major cause of morbidity and mortality.4–7 
RD-ILDs represent the second most common diagnosis in 
tertiary ILD referral centres.8 In particular, ILD can complicate 
connective tissue diseases (CTDs) and rheumatoid arthritis 
(RA), yet it also complicates antineutrophil cytoplasmic 
antibody (ANCA)-associated vasculitis (AAV) and sarcoidosis, 
with variable prevalence and different grade of severity of 
pulmonary involvement and mortality rate according to the 
specific RD.5,9–17 Moreover, increasing interest and a deeper 
knowledge have been emerged regarding a subgroup of 
patients with ILD and clinical and/or serological findings 
suggestive but not diagnostic for a definite RD, defined as 
interstitial pneumonia with autoimmune features (IPAF).18–20 
RD-ILD can be characterized by all the histological/radiological 
patterns described for idiopathic interstitial pneumonias.4,21 
Some authors speculated about more favourable responses 
to immunosuppressive therapy for non-specific interstitial 
pneumonia (NSIP) or organizing pneumonia patterns. However, 
no strong evidence-based data support this hypothesis.22,23 
The pathogenesis of ILD in CTD, AAV, and IPAF shares some 
similarities and is substantially characterized by long-term 
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and aggressive systemic inflammation and immune activation 
with consecutive damage to lung tissues and the development 
of a profibrotic microenvironment.15,24–28 The main actors of 
the fibrotic process are inflammatory cytokines, activated 
macrophages, fibroblasts, T and B cells, adaptive immunity 
and antibodies, and reactive oxygen species.15,24–28 Usual 
interstitial pneumonia (UIP) in RD-ILD also shows analogies 
with idiopathic pulmonary fibrosis (IPF), in particular regarding 
their natural history and clinical behaviour with a progressive 
fibrosing phenotype.29–31 Moreover, the same genetic 
predisposition has been described for the IPF and UIP patterns 
in RA-associated and AAV-associated ILDs.31–35 Finally, similarly 
to IPF, patients with RD-ILD may also experience an acute 
exacerbation (AE).36
The management of ILD in patients with RD is challenging and 
could be decisive to improve their quality of life and decrease 
mortality and the high utilization of healthcare resources. 
However, due to the paucity of randomized controlled trials 
(RCTs) and the substantial heterogeneity in disease behaviour, 
the therapeutic choice for RD-ILD is currently based on an 
empirical approach dependent on the personal experience and 
expertise of the medical team. The best available evidence  
has been generated in systemic sclerosis-associated ILD  
(SSc-ILD).37,38
Several therapeutic agents have been suggested and current 
treatment is essentially based on immunosuppression. 
The scientific background supporting the use of an 
immunosuppressive drug in RD-ILD comprises a direct anti-
inflammatory effect on the primary aetiopathogenetic process 
of ILD and an indirect effect by decreasing the RD activity, 
which could influence the ILD progression. Recently, the use of 
antifibrotic agents has also been proposed.30,37,38
The pharmacological immunosuppressive properties of MMF, 
as described (see pharmacodynamic effects section) support 
the scientific rationale for the use of MMF as a treatment for 
severe RD-ILD. Indeed, MMF is usually considered the main 
alternative to cyclophosphamide (CYC) as a first-line agent to 
treat RD-ILD or as possible maintenance therapy after CYC, with 
a lower rate of side-effects.3,39–42
In this review, we describe the available data and recent 
advances on the effectiveness and safety of MMF for the 
treatment of ILD related to RD, including RA, SSc, primary 
Sjögren syndrome (pSS), systemic lupus erythematosus (SLE), 
idiopathic inflammatory myopathies (IIMs), undifferentiated 
CTD (UCTD), IPAF, and AAV (Table 1).
Methodology and study selection
A systematic literature review was conducted by two authors 
(GC and CV) using PubMed, Web of Science, Scopus, Embase, 
Latin American and Caribbean Health Sciences Literature, 
and Cochrane Central databases. The research strategy was 
((mycophenolate mofetil* OR mycophenolate sodium*) 
AND (interstitial lung disease* OR interstitial pneumonia* 
OR lung fibrosis*) AND (rheumatoid arthritis* OR connective 
tissue diseases* OR systemic sclerosis* OR primary Sjögren 
syndrome* OR systemic lupus erythematosus* OR idiopathic 
inflammatory myopathies* OR undifferentiated CTD* OR 
interstitial pneumonia with autoimmune features* OR 
ANCA-associated vasculitis* OR small vessel vasculitis* 
OR sarcoidosis*)) in the text, title, and abstract fields. We 
considered RCTs, systematic reviews, observational studies, 
case series, and case reports. We did not consider abstract 
or grey literature. We also used the snowballing technique 
to search the bibliographies for relevant references from the 
reference list or moving forward to the citing articles. No 
language restriction was considered, no years of publication 
restriction were applied, and only published articles were 
considered. A narrative review was conducted due to the low 
quality of available studies, consisting mainly of case reports or 
case series and retrospective studies.
Pharmacological properties of 
MMF
Clinical pharmacokinetics
MMF is an ester of MPA and was synthesized to increase the 
bioavailability of MPA. Following administration, MMF is 
rapidly and completely absorbed and is entirely metabolized 
by liver carboxylesterases 1 and 2 to MPA by a pre-systemic 
de-esterification. MPA is almost completely metabolized by the 
enzyme glucuronyl transferase to the pharmacologically inactive 
and stable phenolic glucuronide MPAG, which is excreted in 
urine and represents almost all of the administered dose. The 
glucuronide metabolite is then converted to MPA through 
enterohepatic recirculation. MMF escaping metabolism in the 
intestine enters the liver via the portal vein and is transformed 
to pharmacologically active MPA in the liver cells. In addition 
to MPAG, other major metabolites of MPA are MPA acyl-
glucuronide, 7-O-MPA glucoside, and small amounts 6-O-des-
methyl-MPA. 
Almost all of the whole administered dose is excreted in the 
urine as MPAG. The average apparent half-life of MMF is 17.9 
(±6.5) hours after oral administration and 16.6 (±5.8) hours 
after intravenous administration. Plasma clearance of MMF is 
193 mL/min after an oral dose and 177 (±31) mL/min after an 
intravenous dose. Effectively, oral MMF is 100% bioavailable 
as MPA in healthy individuals. These properties of MMF lead 
to a small intra-individual and inter-individual variability for 
plasma MPA and to predictable pharmacokinetics changes in 
pathophysiological situations.43,44
Pharmacodynamics
The immunosuppressive effects of MMF are mainly derived 
from its cytostatic effect on T and B lymphocytes and, 
hence, on the inhibition of antibody production. Three other 
mechanisms may also contribute to the anti-inflammatory 
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Table 1. Available evidence for the use of mycophenolate mofetil in RD-ILD.
Author, year (ref.) Article type Number of patients
Rheumatoid arthritis
Fischer et al., 2013 (40) Retrospective 18
Oldham et al., 2016 (66) Retrospective 8
Saketkoo et al., 2008 (41) Case series 3
Systemic sclerosis
Tashkin et al., 2016 (42) RCT: SLS II 63
Volkmann et al., 2017 (70) RCT: SLS I-II 69
Naidu et al., 2020 (71) RCT 20
SLS III (NCT03221257) (94) RCT: SLS III NA
Stratton et al., 2001 (73) Prospective 13
Liossis et al., 2006 (85) Prospective 6
Vanthuyne et al., 2007 (86) Prospective 16
Derk et al., 2009 (82) Prospective 15
Simeón-Aznar et al., 2011 (83) Prospective 14
Mendoza et al., 2012 (81) Prospective 25
Panopoulos et al., 2013 (92) Case–control 26
Tzouvelekis et al., 2012 (77) Retrospective + systematic review 10 (total 69)
Nihtyanova et al., 2007 (78) Retrospective 109
Zamora et al., 2008 (88) Retrospective 17
Gerbino et al., 2008 (87) Retrospective 13
Koutroumpas et al., 2010 (74) Retrospective 10
Le et al., 2011 (75) Retrospective 98
Owen et al., 2016 (89) Retrospective 18
Baqir et al., 2017 (91) Retrospective 46
Adler et al., 2018 (79) Retrospective NA
Saketkoo et al., 2009 (68) Case series 4
Yilmaz et al., 2014 (80) Case series 12




Morganroth et al., 2010 (106) Retrospective 16
Mira-Avendano et al., 2013 (103) Retrospective 9
Hanaoka et al., 2019 (104) Retrospective 19
Huapaya et al., 2019 (105) Retrospective 44
Cozzani et al., 2013 (110) Case report 1
Girard et al., 2013 (128) Case report 1
Sundaragiri et al., 2014 (116) Case report 1
(Continued)
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activity of MMF.1–3,45 First, MMF can induce apoptosis of 
activated T lymphocytes and suppress the T lymphocytic 
response to allogeneic cells and other antigens. MPA also 
suppresses dendritic cell maturation decreasing their capacity 
of antigen presentation to T lymphocytes. Second, MMF 
inhibits the glycosylation and expression of adhesion molecules 
as well as the recruitment of lymphocytes and monocytes into 
sites of inflammation. Third, by depleting tetrahydrobiopterin, 
MMF decreases the production of NO by inducible NO synthase 
and the consequent tissue damage mediated by peroxynitrite. 
Moreover, by decreasing the recruitment of monocyte-
macrophage lineage cells, MMF decreases the production of 
TNFα and IL-1, both of which are cytokines implicated in the 
recruitment and proliferation of fibroblasts.
Adverse effects and contraindications
MMF is usually safer and better tolerated than CYC. 
Unlike azathioprine (AZA), the deficiency in thiopurine 
methyltransferase is not a potential concern when prescribing 
MMF. On the contrary, MMF should theoretically be avoided in 
patients with the rare hereditary deficiency of hypoxanthine-
guanine phosphoribosyl transferase (e.g. Lesch–Nyhan or 
Kelley–Seegmiller syndromes).
Adverse effects and monitoring
Gastrointestinal (GI) symptoms and bone marrow suppression 
are the most frequent adverse effects of MMF. Other 
common side-effects include hepatitis and increased risk of 
Table 1. (Continued)
Author, year (ref.) Article type Number of patients
Tsuchiya et al., 2014 (109) Case report 1
Kulkarni et al., 2015 (117) Case report 1
Gil et al., 2016 (108) Case report 1
Hayashi et al., 2017 (126) Case report 1
Hisanaga et al., 2017 (127) Case report 1
Koyama et al., 2017 (107) Case report 1
Ruegg et al., 2019 (115) Case report 1
Systemic lupus erythematosus
Al Rashidi et al., 2011 (132) Case report 1
UCTD and IPAF




Brill et al., 2013 (147) Retrospective 10
Hamzeh et al., 2014 (146) Retrospective 37
Papiris et al., 2019 (145) Retrospective 8
Other articles: cumulative data on more diseases or drugs
Zhang et al., 2015 (67) RCT 23 RD-ILD 
Swigris et al., 2006 (39) Retrospective 28 RD-ILD
Saketkoo et al., 2009 (68) Retrospective 10 RD-ILD
Fischer et al., 2013 (40) Retrospective 125 RD-ILD
ANCA, antineutrophil cytoplasmic antibody; ILD, interstitial lung disease; IPAF, interstitial pneumonia with autoimmune 
features; NA, not available; RCT, randomized controlled trials; RD, rheumatoid disease; SLS, Scleroderma Lung Study; UCTD, 
undifferentiated connective tissue disease.
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infections. A higher risk of cancer and progressive multifocal 
leukoencephalopathy have also been described.46,47
Common and uncommon side-effects of MMF are listed in 
Table 2. GI side-effects are usually dose related and tend to 
reduce over time. In patients with GI intolerance to MMF 
(mainly diarrhoea), the enteric-coated mycophenolate sodium 
can be an alternative formulation. However, it has not been 
formally tested in any controlled studies, and some authors 
demonstrated similar rates of GI side-effects for both drugs.48,49 
In some patients, compliance improves by increasing the 
number of divided daily doses (maintaining the same total 
daily dose). Other patients may require dose adjustments. 
In patients with active peptic ulcer or other GI disease, such 
as inflammatory bowel diseases, MMF should be used with 
caution.
Cytopenia is the major potential concern and requires regular 
monitoring, which should also include renal and liver function 
and signs of lymphoma or myeloproliferative disorders.50 The 
risk for malignancies, mainly lymphoproliferative disorders, 
is related to the intensity and duration of therapy. Moreover, 
even if a direct association between lung fibrosis and cancer 
is still missing, emerging evidence, mainly in IPF, suggest 
that progressive lung fibrosis represents a risk factor for lung 
cancer development. In IPF, lung cancer often occurs in the 
peripheral areas and lower lobes where fibrotic changes 
are predominant.51 Furthermore, radiologic features of 
RD-ILD and lung cancer can overlap substantially. Thus, the 
interpretation of chest high-resolution computer tomography 
(HRCT) can be difficult and should be done with caution, 
notably regarding atypical nodes or masses and/or lymph 
nodes.52
There are no large studies examining the incidence of 
infections in patients with rheumatic illness treated with MMF. 
The existing studies53,54 are too small to allow generalizations. 
On the other hand, data from larger studies regarding solid 
organ transplants showed conflicting results.55–57
MMF has antimicrobial properties and seems to exert a 
protective effect against Pneumocystis jirovecii.58,59 Therefore, 
the use of prophylaxis for Pneumocystis pneumonia is 
controversial. The association between MMF and possible 
viral infections, such as herpes zoster and cytomegalovirus 
infection, is also disputable.60–63 
Nevertheless, patients with RD are not directly comparable 
to patients with solid organ transplants. In fact, in patients 
with RD, the increased risk of infections can derive from the 
exposure to other immunosuppressive agents and to higher 
cumulative doses of corticosteroids (CSs).64 Furthermore, the 
aetiopathogenetic alteration of the immune system in RD may 
lead itself to an increased susceptibility to infections. 
In addition, pulmonary infections can be more frequent 
and more severe in a context of ILD.64 Infections have been 
suggested to play a role both in the pathogenesis of ILD and 
as potential triggers of AE, mainly in IPF. Thus, diagnosis and 
treatment of acute lower respiratory tract infections as early as 
possible is required to prevent a life-threatening condition like 
AE. In this context, the use of an immunosuppressive drug such 
as MMF, especially in combination with high-dose steroids, 
may increase the risk of severe pulmonary complications and 
mortality in patients with RD-ILD.65
For all these reasons, vaccinations, excluding live attenuated 
vaccines, are highly recommended in patients with rheumatic 
conditions who take MMF. 
Contraindications
MMF has been associated with an increased risk of congenital 
abnormalities and should be avoided during pregnancy. Reliable 
contraception should be employed by women of childbearing 
age. MMF is excreted in breast milk and is contraindicated 
during breastfeeding. A pregnancy test should be performed 
immediately prior to initiation and 8–10 days later in females of 
childbearing age, followed by repeat tests during therapy.
Rheumatoid arthritis
ILD is the most common manifestation of lung involvement in 
RA. Unlike CTD-ILD, the most common histopathologic type is 
UIP. In addition to the histological/radiological pattern, RA-ILD 
shares many other analogies with IPF. It shows a similar clinical 
behaviour, often with a progressive fibrosing phenotype, and a 
comparable prognosis and survival.29–31 
Evidence-based use of MMF in RA-ILD is still missing; moreover, 
it is ineffective for the articular manifestations of the disease. 
No controlled studies are available to recommend the use of 
MMF in RA-ILD.40,41,66–68 Saketkoo et al.68 described a clinical 
improvement in physiological lung assessment and radiological 
stabilization in a small case series of three patients with RA-ILD. 
In 2016, a retrospective study from the UK observed a better 
survival of patients with RA-ILD treated with MMF than with 
AZA.69 The relative risk of death for any cause was increased in 
patients treated with prednisone, whereas it was unaltered for 
AZA and decreased for MMF. The authors suggested a better 
outcome following treatment with MMF rather than with 
CSs or AZA in patients with RA-ILD. In a series of 125 patients 
with CTD-ILD, including 18 with RA, MMF was associated with 
modest improvements in forced vital capacity (FVC) and in 
diffusing capacity of the lungs for carbon monoxide (DLCO) and 
a reduction in the prednisone dose.40 Finally, in 2016, Oldham 
et al.66 compared the use of AZA and MMF in patients with 
fibrotic CTD-ILD, including 15 patients with RA-ILD. Both groups 
demonstrated pulmonary function stability over time, with 
the AZA group demonstrating a marginal improvement but 
much more side-effects.
Connective tissue diseases
MMF is one of the most common immunosuppressive agents 
currently used for the treatment of CTD-ILD. However,  
there have been no prospective studies about the safety or 
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Table 2. Side-effects of mycophenolate mofetil. Incidences include concomitant use of corticosteroids and other 
immunosuppressants.
>10% 1% to 10% Rare
Cardiovascular Hypertension, hypotension, 








Pain, headache, insomnia, dizziness, 
depression, chills, confusion, 
drowsiness, hypertonia, malaise, 
myasthenia, paraesthesia
Anxiety, fatigue Meningitis, progressive multifocal 
leukoencephalopathy







hypocalcaemia, increased lactate 
dehydrogenase, hyperkalaemia, 
acidosis, weight loss, hyperuricaemia, 
hyperlipidaemia, hypophosphataemia
Diabetes mellitus
Gastrointestinal Abdominal pain, nausea, diarrhoea, 
constipation, vomiting, decreased 
appetite, dyspepsia, oesophagitis, 
gastric ulcer, gastritis, gastrointestinal 
haemorrhage, hernia of abdominal 
cavity, intestinal obstruction, 








anorexia, colitis, duodenal ulcer, 
oesophageal ulcer, gastrointestinal 
perforation, haematemesis, 
haemorrhagic colitis, haemorrhagic 
gastritis, melena, pancreatitis, 
peritonitis
Genitourinary Urinary tract infection, haematuria Urinary retention 
Haematologic 
and oncologic
Leukopenia, anaemia, leukocytosis, 
thrombocytopenia, benign skin 
neoplasm, disorder of haemostatic 








Agranulocytosis, bone marrow 
failure, hypogammaglobulinaemia 
lymphadenopathy, lymphopenia, 
pure red cell aplasia
Hepatic Increased liver enzymes, hepatitis, 
increased serum alkaline phosphatase
Abnormal hepatic 
function tests
Infection Bacterial infection, viral infection, 
cytomegalovirus disease, fungal 
infection
Influenza, wound 
infection, herpes simplex 
infection, herpes zoster 
infection, sepsis
Protozoal infection, atypical 
mycobacterial infection, BK virus, 
polyomavirus infection, reactivation 
of Hepatitis C virus (HCV), 




Asthenia, tremor, back pain, arthralgia Muscle cramps, myalgia, 
peripheral pain 
Osteomyelitis
Renal Increased serum creatinine, increased 
blood urea nitrogen
Renal insufficiency, renal 
tubular necrosis 
Respiratory Dyspnoea, cough, pleural effusion Dyspnoea on exertion, 
nasopharyngitis, 
pneumonia, sinusitis, 
upper respiratory tract 
infection
Pharyngitis, respiratory tract 
infection, bronchiectasis interstitial 
pulmonary disease, pulmonary 
oedema, pulmonary fibrosis, 
wheezing, xerostomia
Miscellaneous Fever
This table is adapted from the Medication Guide of MMF.44
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efficacy of this approach. The best available evidence has  
been generated only in a small number of RCTs for  
SSc-ILD.37,42,70,71
MMF demonstrated stability of lung function and a low  
rate of adverse events in a small cohort of patients with  
mixed CTD-ILD.39,40,67,68 In another longitudinal retrospective 
study of 125 patients with CTD-ILD, MMF seemed to either 
stabilize or improve FVC and DLCO over a median of  
2.5 years of follow-up, with a low rate of discontinuation.40  
In CTDs and vasculitides, MMF is largely used for the treatment 
of systemic manifestations other than lung involvement as 
well as for maintenance after induction therapy with other 
immunosuppressants such as CYC. Unfortunately, it is not 
effective in treating joint arthritis.
Systemic sclerosis
ILD is a frequent complication of SSc, often progressive and 
with a poor prognosis. The most common histopathologic 
subtype is NSIP.72 However, the optimal treatment and the 
therapy’s timing for SSc-ILD is still area of uncertainty. Since 
2001, many retrospective reviews and small prospective 
case series68,73–88 have assessed the role of MMF in SSc-ILD, 
providing encouraging results in terms of improvement or 
stability in lung function and symptoms as well as a good 
safety profile.
In 2015, Omair et al.76 performed a systematic review to 
evaluate the GI adverse events of MMF in patients with SSc. The 
secondary end-point was the evaluation of the effectiveness 
of the drug on lung disease in terms of pulmonary function 
tests (PFTs). Among 13 studies included, 7 observational studies 
reported improvement or stabilization in FVC.68,73–76,81–88 
According to Omair et al.,76 the Australian Scleroderma Cohort 
Study and Japanese Respiratory Society observed stability or 
improvement in FVC in patients with SSc.89,90 In 2017, another 
retrospective study of 46 patients with SSc-ILD treated for at 
least 1 year showed that the use of MMF slowed the rate of 
decline of lung function, even at doses lower than 3 g/day.91 
On the contrary, Panopoulos et al.92 cautioned about replacing 
CYC with MMF in SSc-associated ILD. A deterioration of lung 
HRCT findings at 2 years was noticed in the MMF group but 
not after CYC, even if the CYC group had more extended ILD 
at baseline. Recently, a network meta-analysis compared the 
efficacy and safety of different treatments in SSc-ILD. Compared 
to the placebo, MMF did not significantly reduce FVC decline 
nor DLCO.93
To date, only two RCTs have evaluated the safety and efficacy of 
MMF in patients with SSc-ILD.42,70 The Scleroderma Lung Study 
(SLS) II included 142 patients with moderate-to-severe SSc-ILD. 
It compared MMF 3 g daily for 2 years with oral CYC for 1 year 
finding no differences in efficacy but better tolerance to MMF.42 
The average FVC presented a modest decline between 21 and 
24 months of follow-up in both arms, and a complete loss of 
efficacy was not observed in the CYC arm, as occurred in SLS I. 
Notably, DLCO decreased in both groups, although this finding 
was significantly greater in the CYC versus the MMF group. 
The study also demonstrated a greater safety and tolerability 
of MMF compared with CYC, although no differences in the 
incidence of infection, bleeding, or death were recorded.42 
Volkmann et al. compared the outcomes for the MMF arm of 
SLS II with the placebo arm of SLS I.70 Considering the limits 
inherent in the design of the study, MMF showed a long-lasting 
efficacy on PFT parameters and dyspnoea and showed a high 
safety profile.
Recently, a double-blind, randomized, placebo-controlled, 
pilot trial conducted at a tertiary care hospital in north India 
(NCT02896205) aimed to assess the efficacy and safety of MMF 
in patients with SSc-ILD and mildly impaired lung function 
(FVC ≥70% predicted); 41 patients were included in the 
study, and treatment with MMF did not result in a significant 
improvement of lung function over 6 months.71 Finally, SLS 
III (NCT03221257) is now ongoing to compare the efficacy of 
MMF alone or in combination with pirfenidone in patients 
with active and symptomatic SSc-ILD. The estimated study 
completion date is in March 2022 and no preliminary data are 
available yet.94
Primary Sjögren syndrome
ILD is the most frequent pulmonary manifestation of pSS. 
Although not frequent, lymphoid interstitial pneumonia is 
the radiological/histological pattern most closely associated 
with pSS. Recent studies indicated UIP as the most frequent 
pattern in pSS patients.95 Lung hematologic malignancies have 
also been described.96 Management strategies for Sjogren-
associated lung diseases (pSS-ILD) remain empiric because no 
controlled studies have been performed.
The few available data about MMF in pSS are extrapolated from 
retrospective studies describing mixed cohorts of patients with 
CTD-ILD. These small case series suggest that MMF may be 




ILD represents the most common non-muscoloskeletal 
manifestation of IIMs.97 The majority of patients with IIM who 
develop ILD have a clinical and histopathological pattern of 
NSIP or organizing pneumonia; thus, immunosuppressants 
are usually the first therapeutic choice.97,98 No evidence-based 
guidelines exist regarding IIM-ILD therapy regimens.99 Most 
patients follow a chronic, slowly progressive course that 
does not require specific treatment. However, early evidence 
suggests that some subtypes of antibodies correlate with 
the development of ILD and with worse severity,98,100–102 as 
mentioned below. Immunosuppressants are usually the first 
therapeutic choice in those patients.
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A retrospective review of treatment outcomes in IIM-ILD 
reported the same efficacy in stabilizing lung function and in 
glucocorticoid dose tapering for oral CYC, AZA, and MMF.103 In 
2019, Hanaoka et al. evaluated the efficacy and tolerability of 
MMF alone (12 patients) or associated to calcineurin inhibitors 
(7 patients) in resistant inflammatory myopathy. No significant 
improvement in %FVC and HRCT images and no differences 
in death or ILD progression were found in patients with ILD in 
either group.104 In the largest cohort of IIM-ILD treated with 
MMF,105 44 patients showed improvement in FVC and in reaching 
lower prednisone dose, but no improvement of the DLCO was 
detected. Apart from these studies, only sporadic small case 
series and case reports are available on this topic.39,40,67,68,106–110
Antisynthetase syndrome
ILD is a hallmark of antisynthetase syndrome (ASSD), with 
a prevalence ranging from 67% to 100% of cases.111 This 
IIM is characterized by the presence of antiaminoacyl-tRNA 
synthetase antibodies.112,113 Anti-Jo1 positivity has been shown 
to have a favourable prognostic value; on the contrary, anti-
PL7 and anti-PL12 autoantibodies are often associated with a 
more aggressive ILD and a poor survival.100,101,114 In the study 
by Mira-Avendano et al.,103 approximately 50% of the patients 
were positive for anti-Jo1. As mentioned earlier, the use of CYC, 
AZA, or MMF was similarly associated with the stability of PFTs, 
a reduction in dyspnoea, and the steroid dose. Other anecdotal 
case reports showed similar results in patients with ASSD 
positive for anti-Jo1 antibodies.115–117
No studies have directly evaluated the efficacy and safety 
of MMF in non-anti-Jo1 ASSD patients. Non-anti-Jo1 
antisynthetase antibodies (anti-KS, anti-OJ, anti-EJ, anti-PL-7, 
anti-PL-12) are less frequent in ASSD. Therefore, evidence for 
these specific subgroups is very poor. However, many patients 
with these autoantibodies are included in studies on CTD-ILD 
or IIM-ILD. It has been suggested that patients with anti-KS 
and anti-OJ antibodies would be most likely to have a good 
response to CSs.118,119 
Antimelanoma differentiation-associated 
gene 5 (MDA5) dermatomyositis
Anti-MDA5-positive dermatomyositis is characterized by an 
elevated risk of ILD with a rapidly progressive and potentially 
fatal course.120–124 The 6-month survival rate in some studies 
is 40% despite therapies.125 In 2017, Hayashi et al.126 described 
the case of a patient with anti-MDA5-ILD successfully treated 
by the addition of MMF to an immunosuppressive therapy 
including CSs, oral cyclosporine, and intravenous CYC. The 
same year, Hisanaga et al.127 presented a case of worsening ILD 
despite treatment with high-dose prednisolone combined with 
cyclosporine and intravenous CYC in a patient positive for anti-
MDA5. The addition of direct hemoperfusion with polymyxin-B, 
MMF, intravenous immunoglobulin, and rituximab (RTX) led 
to remission of the disease. On the other hand, Girard et al.128 
reported a case of anti-MDA5-ILD treated with intravenous 
immunoglobulins, CYC, MMF, AZA, and RTX in combination 
with oral CSs, without any improvement in respiratory function. 
Gil et al.108 described a case series of patients with clinically 
amyopathic dermatomyositis-ILD, including a patient with 
anti-MDA-5 antibodies who received MMF and intravenous 
immunoglobulins. The patient died of pneumonia 30 months 
after initial presentation.
Systemic lupus erythematosus
ILD can rarely complicate SLE,129,130 and evidence for the 
treatment of SLE-ILD is of low quality, as no clinical trial or 
guidelines are available. A consensus conference on the 
management of SLE in 2015 proposed the use of MMF as 
induction therapy in association with corticosteroids in patients 
with lung involvement. MMF was also indicated as maintenance 
strategy or for the treatment of mild-to-moderate disease.131 Only 
one case report described the use of MMF for SLE-related diffuse 
alveolar haemorrhage, with some efficacy as a maintenance 
therapy (no further diffuse alveolar haemorrhage episodes).132 
Only one of ten patients with CTD-ILD had a diagnosis of SLE in 
the case series by Saketkoo et al.,68 while Fisher et al.40 included 
four patients with SLE-ILD in their retrospective study. 
Undifferentiated CTD
ILD can be a clinical manifestation of UCTD, even if the 
available classification criteria do not consider lung 
manifestations in UCTD.133 The management of ILD-UCTD 
is usually based on immunosuppression, including MMF. 
However, no evidence-based therapeutic regimens are 
available to date. 
Interstitial pneumonia with autoimmune 
features
IPAF is a clinical condition characterized primarily by ILD 
associated to other features (clinical, serological, and/or 
morphological) suggestive of a CTD that does not meet 
established classification criteria for a given autoimmune 
disease.18 For IPAF, both the use of immunosuppressants134–137 
and antifibrotic agents138–140 have been proposed. 
Unfortunately, to date, no controlled clinical trials are available 
to guide evidence-based therapeutic regimens. McCoy et 
al.135 recently described a retrospective case–control series of 
28 patients with IPAF exposed to MMF. Changes in FVC% and 
DLCO% between the MMF-treated and -untreated groups were 
not significantly different. In patients treated with MMF, FVC 
and DLCO slightly improved after exposure to the drug but 
without statistical significance. 
ANCA-associated vasculitis
Pulmonary involvement is frequently observed in AAV 
patients, and ILD is an emerging possible phenotype. The 
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to treat oncologic disorders and to prevent acute allograft 
rejection after organ transplant. 
As for other immunosuppressive agents in relation to RD-ILD, 
the use of MMF is supported by poor scientific evidence. Its 
efficacy has only been demonstrated by three RCTs in patients 
with SSc, with questionable results.42,70,71 Furthermore, MMF 
is often used in association with CSs with high heterogeneity 
in drug dosages and timing, making it difficult to extrapolate 
efficacy data on the single drug. Of note, all patients 
evaluated in retrospective studies describing the use of MMF 
in mixed RD-ILD were treated with concomitant CSs.39,40,67,68
Numerous other therapies have been proposed for RD-ILD, 
including novel agents such as antifibrotics, and biologic and 
non-biologic disease-modifying antirheumatic drugs. Clinical 
trials are ongoing.37,38 However, the manageable use of the 
‘old drug’ MMF, its low rate of side-effects, the clinicians’ 
decades of experience in its use in real life, and the lack of 
other evidence make MMF a preferred therapeutic option for 
the treatment of severe forms of RD-ILD. The decision to  
start therapy in patients with RD-ILD should be evaluated 
in the single patient, balancing comorbidities, the possible 
adverse effects of treatment, and disease prognosis in each 
patient. 
Moreover, the immunosuppressants historically used for the 
treatment of ILD, such as MMF as well as CYC and AZA, are 
usually of low efficacy for the articular manifestations of most 
RD. CYC is widely used in the treatment of RD-ILD, and it is 
usually the first choice in patients with rapidly progressive ILD. 
A recent systematic review found that a small benefit may be 
derived from the use of CYC in CTD-ILD when compared with 
placebo but not when compared with MMF.148 In particular, 
no significant impact on health‐related quality of life, all‐cause 
mortality, dyspnoea, or cough severity was found in the CYC 
group compared with the MMF group. Only four RCTs were 
included in the analysis, mostly on SSc, and the evidence was 
found to be of low quality as dropout rates were high in the 
intervention groups. Moreover, the risk of side-effects was 
increased with CYC versus MMF, in particular leukopenia and 
thrombocytopenia.
Among the disease-modifying antirheumatic drugs, the use 
of RTX has been suggested for RD-ILD, mainly in case reports 
and retrospective uncontrolled studies, showing encouraging 
short-term and long-term results with an acceptable safety 
profile.37,38 Recently, Atienza-Mateo et al.149 published a 
retrospective single centre study focusing on RTX in the 
treatment of RD-ILD. They found a sustained improvement in 
PFTs and a statistically significant increase in DLCO in patients 
treated with RTX, regardless of the radiological pattern or the 
underlying RD. However, only one RCT including eight patients 
with SSc-ILD150,151 and a nested case–control study152 have 
been published. No results from the RECOVER and RECITAL 
trials are yet available.153,154 
The use of abatacept, tocilizumab, and Jak inhibitors for RD-ILD 
has also been proposed in anecdotal reports.37,38,155–157
prevalence of ILD is higher in microscopic polyangiitis than 
in granulomatosis with polyangiitis, and anti-MPO antibodies 
are the main ANCA subtype associated to ILD. Lung fibrosis in 
oeosinophilic granulomatosis with polyangiitis or associated to 
anti-PR3 is rare.141 Cases of patients positive for ANCA, mainly 
MPO-ANCA, without vasculitis and concomitant ILD have also 
been reported in the literature. Only retrospective case series 
and a few case reports have been published and no controlled 
clinical trials are available to guide the treatment of AAV-ILD or 
ANCA-positive ILD.
Despite contrasting data, standard treatment of systemic 
vasculitis is also considered for ILD and includes systemic 
glucocorticoids with or without immunosuppressants.141,142 
MMF is mainly used both as remission and maintenance 
therapy143 and its efficacy was demonstrated in all the clinical 
aspects of AAV. Immunosuppressive agents, including MMF, are 
also considered for the treatment of NSIP pattern, despite the 
presence of systemic vasculitis.141
Sarcoidosis
Sarcoidosis is a granulomatous systemic disease of unknown 
aetiology. Pulmonary involvement is present in about 90% of 
cases. Usually, pulmonary sarcoidosis is self-limited and does 
not require treatment. However, some patients may develop 
chronic progressive pulmonary involvement with fibrotic 
alterations, requiring long-term therapy with CS and/or other 
immunosuppressants as CS-sparing agents.144 
The effect of MMF on chronic pulmonary sarcoidosis has 
been poorly investigated. A retrospective study evaluated 
the effectiveness and safety of MMF in eight patients  
with both pulmonary and extrapulmonary sarcoidosis.  
A statistically significant improvement in FVC was reported, 
and symptoms and chest radiological findings improved in 
all patients.145 On the contrary, another retrospective study of 
37 patients with sarcoidosis found no statistically significant 
changes in PFT or DLCO measurements both before and 
after MMF therapy.146 Finally, Brill et al.147 retrospectively 
investigated the efficacy of MMF and systemic CSs in ten 
patients with biopsy-proven chronic pulmonary sarcoidosis. 
Pulmonary function, symptoms, and radiological signs 
improved in four patients, while six patients remained stable 
after 6 months.
Discussion
Although the pathogenesis of RD-related pulmonary disease 
is poorly understood, there is an assumption that it arises as 
a sequela of immune-mediated injury to the lung. As a result, 
immunosuppressive agents still represent the mainstay of 
treatment for RD-ILD.
MMF is an antimetabolite with a potent inhibitory effect on 
proliferation of T and B lymphocytes. MMF is well known and 
widely used since the early 1990s as immunosuppressant 
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pathogenesis of RD-ILD and the availability of RCTs – both 
needs are still unmet.
Conclusion
Further prospective, randomized, controlled clinical studies 
are required to better define the long-term efficacy and safety 
of MMF in patients with ILD associated to RD. They should 
be adequately powered to compare outcomes specifically 
within different subgroups and different diseases and stratified 
for histological subtype, disease duration, and extent of 
pulmonary involvement. Researchers may consider comparing 
MMF (as other immunosuppressants) versus other drugs such 
as antifibrotic agents, or comparing both versus placebo, 
in particular for those patients with evidence of rapidly 
progressive fibrotic disease.
Another point to consider is the wide spectrum of clinical 
phenotypes and the heterogeneity in disease behaviour 
of RD as well as of the pulmonary involvement in RD that 
does not allow us to make generalized dissertations on 
this topic. Different diseases may benefit from different 
therapeutic approaches or different timing of treatment. 
The clinical behaviour of pulmonary and extrapulmonary 
manifestation, the presence of comorbidities, and the 
potential adverse effects of treatments globally influence the 
therapeutic approach to the patient. Therefore, treatment 
should be based on the balance between possible benefits 
and burden of disease in each single patient. As a result, a 
multidisciplinary evaluation including at least a rheumatologist 
and pulmonologist, and possibly a radiologist, with expertise 
in ILD, is always recommended. A deeper knowledge on 
how to treat such patients requires clear insights into the 
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